Abstract
AimsMetastatic HER2-low breast cancer (HLBC) can be treated by trastuzumab deruxtecan. Assessment of low levels of HER2 protein expression suffers from poor interobserver reproducibility. The aim of the study was...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have